European biotech argenx N.V.'s efforts to advance its clinical pipeline beyond the closely watched pipeline-in-a-product efgartigimod have hit a snag after partner Johnson & Johnson decided to walk away from a multi-million dollar pact to develop the investigational leukemia drug cusatuzumab.
The Belgian-Dutch biotech, which is listed on the Euronext and NASDAQ exchanges, teamed up with J&J's Janssen unit in December...



![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)

